Pharmaceuticals, Biotechnology & Life Sciences

Merck’s RSV antibody pipeline shows 68% risk reduction in high‑risk infants, but FDA safety reviews may delay launch—investors weigh clinical promise against regulatory risk.

Agilent Technologies’ growth in cell‑therapy analytics and genomic sequencing—backed by high‑margin consumables, AI‑driven software, and value‑based reimbursement—outpaces the life‑sciences sector, fueling investor confidence.

Discover how Astellas Pharma’s precision‑medicine pipeline—targeting ovarian cancer, chordoma, GI oncology and more—drives global growth, market expansion and innovative partnerships.

Kyowa Kirin names COO Abdul Mullick as President & CEO—consolidating leadership for a stronger focus on oncology, immunology and infectious‑disease pipelines, with no immediate impact on clinical or supply‑chain operations.

Waters Corp’s stock hits new highs—boosted by a strong pipeline, 12% revenue growth, and an “Outperform” upgrade, positioning it ahead of peers in analytical tech.

GSK reaffirms a £30bn U.S. expansion, prioritising drug development and manufacturing to tap high‑revenue markets amid new zero‑duty trade terms.

Shanghai Fosun Pharmaceutical’s new drug approval and Pfizer partnership put it in line for early market entry, patent‑cliff protection, and strong global revenue potential.

Recordati’s Enjaymo gains traction amid EU pricing pressure, as the company balances outcome‑based contracts, supply‑chain resilience, and real‑world evidence to secure reimbursement and drive growth.

Goldman Sachs gives Mettler‑Toledo a neutral rating, noting its pivotal role in drug‑development analytics and the growing demand for precision instruments in life sciences.

Grifols SA stock swings on JPMorgan’s 7% target cut vs Qatar’s 2.5% stake hike—see why investors weigh short‑term caution against long‑term growth prospects.